Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26241947 | 0.80 | KDM4E (0.40) | BAZ2BMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL8568508 | 0.79 | SMN1; SMN2 (0.56) | BAZ2BMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL18904958 | 0.79 | BAZ2B (0.53) | BAZ2BMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL3760854 | 0.79 | KDM4E (0.39) | BAZ2BMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL1663229 | 0.79 | GRN (0.56) | PHGDHKDM4EALDH1A1GRNSORT1 | |
| SCHEMBL20519426 | 0.78 | BAZ2B (0.47) | BAZ2BMEN1KMT2ARXFP1SMN1; SMN2 | |
| SCHEMBL286598 | 0.78 | CA12 (0.42) | SMN1; SMN2L3MBTL1KDM4EALDH1A1GRN | |
| SCHEMBL24275920 | 0.77 | BAZ2B (0.37) | BAZ2BMEN1KMT2ASMN1; SMN2SMYD3 | |
| SCHEMBL21961335 | 0.77 | BRD4 (0.47) | BAZ2BBRD4 | |
| SCHEMBL16441391 | 0.77 | BRD4 (0.43) | BAZ2BBRD4KDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2022266193-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022053010-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022053010-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-17 | — | — | WO | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | BAZ2B 49/4885MEN1 4240/4885KMT2A 3564/4885 |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | BAZ2B 2932/4885MEN1 262/4885KMT2A 3870/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | BAZ2B 2932/4885MEN1 262/4885KMT2A 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.